
    
      A registry study is to evaluate the overall survival, use of subsequent anti-cancer therapy,
      and the long-term safety of subjects who have received at least one dose of talimogene
      laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type. Follow-Up
      will occur every 3 months.
    
  